R&D | May 25, 2026
Lilly brings heavy oncology firepower to ASCO with plenary data across cancers
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Subscribe To Our Newsletter & Stay Updated
